XBIO Xenetic Biosciences
- 3.9000
- -0.2350-5.68%
- 3.9050
- +0.0050+0.13%
Xenetic Biosciences News
CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1
Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future
Analysts' Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)
Xenetic Biosciences Reports FY Results
Xenetic Biosciences Q4 EPS $0.77 Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $(0.87) by 188.51 percent. This is a 177 percent increase over losses of $
Xenetic Biosciences Shares Insights on Oncology Platform
Express News | Xenetic Biosciences Enters Into Research Agreement With University Of Virginia For Advancement Of DNase-Based Oncology Platform
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersPHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutic
Xenetic Biosciences (XBIO) Gets a Hold From H.C. Wainwright
Xenetic Biosciences: Q3 Earnings Insights
Xenetic Biosciences (NASDAQ:XBIO) reported its Q3 earnings results on Friday, November 10, 2023 at 08:35 AM.Here's what investors need to know about the announcement.EarningsXenetic Biosciences beat e
Xenetic Biosciences Q3 EPS $(0.69) Beats $(1.12) Estimate, Sales $611.17K Beat $460.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses of $(0
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech
Xenetic Biosciences Reports Results
Xenetic Biosciences Reports Q2 Net Loss $(1.1)M, Cash Balance of $10.7M
Xenetic Biosciences Reports Q2 Net Loss $(1.1)M, Cash Balance of $10.7M
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Xenetic Biosciences Shares Down 15% After Presentation, Tuesday Increase
By Josh Beckerman Shares of cancer-focused Xenetic Biosciences were down 15% to $3.56 Wednesday following a presentation during the Virtual Investor Summer Spotlight Series. The stock rose 23% on Tue
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 10:00 AM ETFRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutica
Analysis
Price Target
No Data
